Newswise — A study led by researchers in the Department of Neurosciences at the University of California, San Diego School of Medicine shows unexpected and extensive natural recovery after spinal cord injury in primates. The findings, to be published November 14 in the advance online edition of Nature Neuroscience, may one day lead to the development of new treatments for patients with spinal cord injuries.
While regeneration after severe brain and spinal cord injury is limited, milder injuries are often followed by good functional recovery.
Millions of people worldwide experience spinal cord injuries. Breakthroughs bring researchers progress, but a complete cure is a long way off
Spinal cord repair focuses on finding ways to make axons regrow and connect properly, replace damaged neurons, protect surviving neurons from further injury and retrain neural circuits to repair body functions.
Oct. 11 (Bloomberg) — Geron Corp. used a therapy made from stem cells taken from human embryos to treat a patient paralyzed by a spinal-cord injury in the first U.S.-authorized test of the technology.
The patient was treated Oct. 8 at Shepherd Center, a rehabilitation hospital in Atlanta, the company said today in a statement. The study is designed to test the safety of Geron’s therapy in patients with spinal cord injuries. The U.S. Food and Drug Administration gave permission in July for Geron to start the study after a halt of almost a year over safety concerns.
Imagine the plight of a young person, the sole bread-earner in the family, getting paralysed below the neck as a result of a road accident, with no movement or sensation in all four limbs and no control over his bowel and bladder. This poses a big physical, psychological and economic challenge not only for the individual but also for the whole family.
Unlike nerves of the spinal cord, the peripheral nerves that connect our limbs and organs to the central nervous system have an astonishing ability to regenerate themselves after injury. Now, a new report in the October 1st issue of Cell, a Cell Press publication, offers new insight into how that healing process works.
“We know a lot about how various cell types differentiate during development, but after a serious injury like an amputation, nerves must re-grow,” said Allison Lloyd of University College London. “They need a new mechanism to do that because the developmental signals aren’t there.”
In a surprising and unexpected discovery, scientists at NYU Langone Medical Center have found that a single type of gene acts as a master organizer of motor neurons in the spinal cord. The finding, published in the September 9, 2010 issue of Neuron, could help scientists develop new treatments for diseases such as Lou Gehrig’s disease or spinal cord injury.
The “master organizer” is a member of the Hox family of genes, best known for controlling the overall pattern of body development.
Neuralstem, Inc. (NYSE Amex:CUR) announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin a Phase I safety clinical trial for chronic spinal cord injury with its spinal cord stem cells. This multicenter Phase I safety trial will enroll a total of 16 long-term, or chronic, spinal cord injury patients, with an American Spinal Injury Association (ASIA) Grade A level of impairment, one-to-two years post-injury. ASIA A refers to a patient with no motor or sensory function in the relevant segments and is considered to be complete paralysis.
The University of California, Irvine, has just completed the very first study to show that human stem cells can bring back movement in spinal cord injury, advocating the possibility of treatment for a more vast populace of patients.
Past breakthroughs in stem cell studies concentrated on the vital or beginning stage of spinal cord injury, a time span of up to a couple of weeks after the onset of the trauma when medications can bring about some mobile recovery.
IRVINE — A UC Irvine study is the first to demonstrate that human neural stem cells can restore mobility in cases of chronic spinal cord injury, suggesting the prospect of treating a much broader population of patients.
Previous breakthrough stem cell studies have focused on the acute, or early, phase of spinal cord injury, a period of up to a few weeks after the initial trauma when drug treatments can lead to some functional recovery.
HOUSTON, Aug. 17 /PRNewswire-USNewswire/ — The United States Department of Defense (DoD) awarded the Christopher & Dana Reeve Foundation a $5.4 million grant to support the expansion of translational research to find treatments for military men and women with spinal cord injuries.
The DoD gave the two-year, peer-reviewed grant to the Foundation’s North American Clinical Trials Network (NACTN), an international network of hospitals led by Dr. Robert G. Grossman, chairman of neurosurgery at the Methodist Neurological Institute in Houston.